Overview

12-week Open-label Evaluation of Efficacy and Safety of Indacaterol

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals